Stock HEMA HEMACARE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News HemaCare Corporation

Equities

HEMA

US4234981045

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for HemaCare Corporation +0.08% +0.24%
2020 HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio CI
2020 MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio
CI
MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials
CI
Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.
CI
Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million.
CI
HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate
CI
HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China
CI
Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019
CI
HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018
CI
HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP
CI
HemaCare Corporation Moves its Global Headquarters to Northridge, California
CI
HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies
CI
HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018
CI
HemaCare Corporation Announces Executive Appointments
CI
HemaCare Corporation Reports Earnings Results for the Full Year Ended December 31, 2017
CI
HemaCare Corporation and Charles River Laboratories International Inc. Announces Strategic Partnership to Accelerate Drug Discovery and Development
CI
HemaCare Corporation Reports Unaudited Earnings Results for the First Six Months Ended June 30, 2017
CI
HemaCare Signs Long Term Lease for Facility Relocation and Expansion
CI
HemaCare Corporation Reports Financial Results for the Year Ended December 31, 2016
CI
HemaCare Corporation Signs Distribution Agreement with Almog Diagnostic
CI
HemaCare Corporation announced that it expects to receive $5 million in funding from OBF Investments LLP
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HEMA Stock
  4. News HemaCare Corporation